跳至主要内容
临床试验/NCT04878458
NCT04878458进行中(未招募)不适用

Effectiveness and Safety of Phacotrabeculectomy and Phacogoniotomy in Advanced Primary Angle-closure Glaucoma: a Multicenter Randomized Controlled Trial

Sun Yat-sen University2 个研究点 分布在 1 个国家目标入组 124 人开始时间: 2021年5月31日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
124
试验地点
2
主要终点
Mean change of intraocular pressure

研究概览

简要总结

A multicenter, parallel, open, non-inferior randomized controlled trial was conducted to compare the effectiveness and safety of phacotrabeculectomy and phacogoniotomy in the treatment of advanced primary angle closure glaucoma, so as to provide a better surgical alternative.

详细描述

Glaucoma is the leading cause of irreversible blindness worldwide, and primary angle closure glaucoma (PACG) accounted for the majority particularly in Asia and China. The preferred treatment method is anti-glaucoma surgery-trabeculectomy (Trab) combined with lens extraction. Phacotrabeculectomy has become the first-line choice of anti-glaucoma suregery in the treatment of advanced PACG. However, it was not an ideal method due to the bleb-related complications and troublesome postoperative nursing, as well as the difficulty for surgeons, caused by trabeculectomy. However, recent studies revealed that the phacoemulsification with intraocular lens implantation (PEI) combined with goniosynechialysis (GSL) has achieved efficacy in the treatment of PACG.

With the advent of minimally invasive glaucoma surgeries (MIGS), there is an increasing number studies indicating the MIGS performed great efficacy in the treatment of primary open angle glaucoma. While,there were a few small-sampled retrospective studies which showed therapeutic effects in PACG. The GSL plus goniotomy (GT) could achieve great efficacy in lowering the intraocular pressure of PACG patients. However, there is still a lack of high quality and high-level randomized controlled trials.

Therefore, this study intends to conduct a multicenter, parallel, open, non-inferior randomized controlled trial to compare the effectiveness and safety of PEI+ Trab and PEI+GSL+GT in the treatment of advanced PACG, so as to provide a better surgical treatment for PACG.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
40 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Inclusion criteria
  • •Aged 40-80 years;
  • •Diagnosed with advanced PACG: meet with (1) (2) (3) or (1) (2) (4)
  • •At least 180-degree PAS under gonioscopy and it should cover the nasal and inferior quadrants for surgical purposes;
  • •IOP >21 mmHg with or without anti-glaucoma medication;
  • •Obvious glaucomatous optic neuropathy (cup-to-disc [C/D] ratio≥0.7, or C/D asymmetry > 0.2, or the rim width at the superior and inferior temporal < 0.1 vertical diameters of optic disc);
  • •With glaucomatous visual field defects, such as nasal step, arcuate scotoma, and paracentral scotoma on a reliable Humphrey analyzer using SITA-Standard 24-2 or 30-2 algorithm; mean deviation ≤ -12dB;
  • •Clinically obvious cataract and uncorrected visual acuity (UCVA) <0.63 (Early Treatment Diabetic Retinopathy Study, [ETDRS] chart), or need lens extraction assessed by a clinician;
  • •Voluntarily participate in study and provide signed informed consent.

排除标准

  • •a. History of ocular surgery (other than laser iridotomy or laser iriplasty) or trauma; b. With other types of glaucoma; (i.e. open angle glaucoma, secondary angle-closure glaucoma, steroidal glaucoma, angle regression glaucoma, neovascular glaucoma, nanophthalmos, pseudoexfoliation syndrome) c. The International Standardized Ratio > 3.0 for patients receiving warfarin or anticoagulant therapy before surgery; d. With retinal disease that affects the collection of ocular parameters; f. Monophthalmia (best-corrected visual acuity [BCVA] <0.01 in the non-study eye); g. With other serious systemic diseases; h. Pregnant or lactating women * If both eyes are eligible for the study, the eye with the worse UCVA will be recruited.

研究组 & 干预措施

PEI+GSL+GT

Experimental

Sixty-two patients with advanced primary angle-closure glaucoma will receive phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy.

干预措施: phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy (Procedure)

PEI+Trab

Experimental

Sixty-two patients with advanced primary angle-closure glaucoma will receive phacoemulsification with intraocular lens implantation combined with trabeculectomy.

干预措施: phacoemulsification with intraocular lens implantation combined with trabeculectomy (Procedure)

结局指标

主要结局

Mean change of intraocular pressure

时间窗: Postoperative 12, 24, 36 months.

Change from baseline IOP after surgery using Goldmann or non-contact tonometer.

次要结局

  • Intraoperative and postoperative complications(0, 1, 7 day. 1, 3, 6, 12, 18, 24, 30, 36 months)
  • Anti-glaucomatous medications(0, 1, 7 day. 1, 3, 6, 12, 18, 24, 30, 36 months)
  • Cumulative success rate of surgery(12, 24, 36 months)

研究者

发起方
Sun Yat-sen University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Xiulan Zhang

Director of Clinical Research Center

Zhongshan Ophthalmic Center, Sun Yat-sen University

研究点 (2)

Loading locations...

相似试验